WG Biotech ApS - 07 Dec 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Director
Signature
WG Biotech ApS by /s/ Johan Wedell-Wedellsborg
Issuer symbol
YMAB
Transactions as of
07 Dec 2023
Net transactions value
+$890,411
Form type
4
Filing time
11 Dec 2023, 17:25:50 UTC
Previous filing
01 Dec 2023
Next filing
12 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Purchase $40,190 +6,183 +0.14% $6.50 4,431,412 07 Dec 2023 Direct F1
transaction YMAB Common stock Purchase $129,379 +18,503 +0.42% $6.99 4,449,915 08 Dec 2023 Direct F2
transaction YMAB Common stock Purchase $720,843 +102,863 +2.3% $7.01 4,552,778 11 Dec 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades each at price of $6.50. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $6.90 to $7.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $6.86 to $7.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and has sole voting and dispositive power over the shares of the Issuer held by WG Biotech ApS. Mr. Wedell-Wedellsborg serves as a director of the Issuer. In connection therewith, WG Biotech ApS may be deemed to be a director by deputization of the Issuer solely for purposes of Section 16(a) of the Exchange Act. As a result, WG Biotech ApS is listed as a "Reporting Person" in Item 1 and the "Director" box is marked in Item 5 of this Form 4. This filing shall not be deemed an admission by Reporting Person on this Form 4 that such person is a director of the Issuer by deputization.